Immunomedics To Report On New Antibody-SN-38 Conjugates And Diverse Novel DNL Agents At AACR 102nd Annual Meeting

MORRIS PLAINS, N.J., March 28, 2011 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that seven posters will be presented at the 102 ^nd Annual Meeting of the American Association for Cancer Research (AACR), April 2 – 6, 2011, in Orlando, FL.

The focus of this year's presentations will be on novel fusion proteins created by the Company's patented Dock-and-Lock (DNL) platform technology. Other presentations will include the development of new antibody-drug conjugates of SN-38, the active metabolite of irinotecan, a drug used for the treatment of cancer.

The schedule and meeting places for the poster sessions, together with the abstract and poster board numbers, are listed below:

• "Dendritic-cell vaccine: Cross-presentation of carcinoembryonic antigen (CEA) by dendritic cells (DCs) through a fusion protein targeting CD74 on DCs" [Abstract No. 755, Poster Session: Cancer Vaccines and Novel Adjuvant Approaches, Sunday, April 3, 1:00 p.m. – 5:00 p.m., Poster Section 31, Poster Board Number 9, Exhibit Hall A4-C]  
• "Effective lymphoma and leukemia therapy with epratuzumab (anti-CD22 IgG) conjugated to SN-38 (Emab-SN-38), with enhanced activity in combination with veltuzumab (anti-CD20 IgG)" [Abstract No. 1798, Poster Session: Novel Combination Immunotherapy Approaches and New Agents, Monday, April 4, 8:00 a.m. – 12:00 p.m., Poster Section 32, Poster Board Number 18, Exhibit Hall A4-C]  
• "HLA-DR-targeting tetrameric IFNα2b immunocytokine has potent in vitro and in vivo activity in myelomas, lymphomas and leukemias" [Abstract No. 1803, Poster Session: Novel Combination Immunotherapy Approaches and New Agents, Monday, April 4, 8:00 a.m. – 12:00 p.m., Poster Section 32, Poster Board Number 23, Exhibit Hall A4-C]  
• "Tolerability in mice, monkeys, and rabbits of new antibody (MAb)-drug (SN-38) immunoconjugates" [Abstract No. 3619, Poster Session: Novel Biologics and Antibody-Drug Conjugates, Tuesday, April 5, 8:00 a.m. – 12:00 p.m., Poster Section 30, Poster Board Number 6, Exhibit Hall A4-C]  
• "Novel antibody-dendrimer conjugates efficiently complex plasmid DNA" [Abstract No. 4445, Poster Session: Novel Drug Delivery Systems, Tuesday, Apr 5, 1:00 p.m. – 5:00 p.m., Poster Section 25, Poster Board Number 18, Exhibit Hall A4-C]  
• "Heterodimerization of CD74 and CD20 by two hexavalent, bispecific, anti-CD20/CD74 antibodies leads to potent cytotoxicity in mantle cell lymphoma" [Abstract No. 4572, Poster Session: Cancer-targeting Antibodies, Tuesday, Apr 5, 1:00 p.m. – 5:00 p.m., Poster Section 31, Poster Board Number 14, Exhibit Hall A4-C]  
• "Pretargeted immunoPET for imaging human colonic cancer in a mouse model" [Abstract No. 5282, Poster Session: In vivo Imaging 1, Wednesday, April 6, 8:00 a.m. – 12:00 p.m., Poster Section 23, Poster Board Number 12, Exhibit Hall A4-C]

About Immunomedics

Immunomedics is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or "naked" form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, in each case to create highly targeted agents. Using these technologies, we have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. We also have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a novel Dock-and-Lock (DNL) methodology with us for making fusion proteins and multifunctional antibodies, and a new method of delivering imaging and therapeutic agents selectively to disease, especially different solid cancers (colorectal, lung, pancreas, etc.), by proprietary, antibody-based, pretargeting methods. We believe that our portfolio of intellectual property, which includes approximately 169 patents issued in the United States and more than 375 other patents issued worldwide, protects our product candidates and technologies. For additional information on us, please visit our website at www.immunomedics.com . The information on our website does not, however, form a part of this press release.

This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials, out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with new product development (including clinical trials outcome and regulatory requirements/actions), our dependence on our licensing partners for the further development of epratuzumab for autoimmune indications and veltuzumab for non-cancer indications, competitive risks to marketed products and availability of required financing and other sources of funds on acceptable terms, if at all, as well as the risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Dr. Chau Cheng         Director, Investor Relations & Grant Management         (973) 605-8200, extension 123         ccheng@immunomedics.com